Compare UBCP & ENTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | UBCP | ENTX |
|---|---|---|
| Founded | 1902 | 2010 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 78.4M | 74.7M |
| IPO Year | N/A | 2018 |
| Metric | UBCP | ENTX |
|---|---|---|
| Price | $14.00 | $1.36 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 3.7K | ★ 266.9K |
| Earning Date | 01-26-2026 | 11-14-2025 |
| Dividend Yield | ★ 6.73% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.31 | N/A |
| Revenue | ★ $30,516,000.00 | $124,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $5.59 | N/A |
| P/E Ratio | $10.61 | ★ N/A |
| Revenue Growth | 4.40 | ★ 25.25 |
| 52 Week Low | $12.25 | $1.36 |
| 52 Week High | $15.64 | $3.22 |
| Indicator | UBCP | ENTX |
|---|---|---|
| Relative Strength Index (RSI) | 50.62 | 31.83 |
| Support Level | $13.85 | $1.52 |
| Resistance Level | $14.15 | $1.59 |
| Average True Range (ATR) | 0.31 | 0.13 |
| MACD | -0.00 | -0.00 |
| Stochastic Oscillator | 42.34 | 9.79 |
United Bancorp Inc operates as a bank holding company that provides commercial and retail banking services. Through its subsidiary (Unified Bank), the company provides a broad range of banking and financial services, which includes accepting demand, savings, and time deposits and granting commercial, real estate, and consumer loans. It serves customers in Belmont, Harrison, Jefferson, Tuscarawas, Carroll, Athens, Hocking, and Fairfield counties and the surrounding localities. The bank also operates in Marshall County West Virginia.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.